To the Editor To date, the CONVERT trial was one of the largest prospective studies evaluating radiation fractionation in limited-stage small cell lung cancer (SCLC).1 The successful execution of the trial by Faivre-Finn et al1 was a major accomplishment to be envied in the United States, where roughly half of patients with limited-stage SCLC do not even receive radiation as part of initial management.2 Salem et al3 presented a secondary analysis of the CONVERT trial that demonstrated the prognostic value of TNM.
Chun SG, Schild SE, Bogart JA. Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer? JAMA Oncol. 2019;5(8):1229. doi:10.1001/jamaoncol.2019.1326
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: